Alnylam advances development candidate for ALN-AAT
New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held 3 May to 6 May 2014 in Chicago, Illinois. ALN-AAT is one
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).